

## Starting Sept. 1, we're replacing Humira with biosimilar drugs for most Medicare Advantage members

Effective Sept. 1, 2025, Medicare Plus Blue<sup>SM</sup> and BCN Advantage<sup>SM</sup> plans will stop covering Humira<sup>®</sup> and will instead cover two Humira biosimilars (adalimumab-aaty and adalimumab-adbm) in its place.

**Note:** UAW Retiree Medical Benefits Trust plan members won't be affected.

Current Humira users have received new authorizations for the covered adalimumab biosimilars so they can continue therapy without interruption. The U.S. Food and Drug Administration has already approved adalimumab-aaty and adalimumab-adbm as interchangeable biosimilars to Humira. A new prescription isn't required for interchangeable biosimilars.

When submitting a prior authorization request for a new patient, select one of the following preferred products:

Preferred adalimumab product	National Drug Code
<b>Adalimumab-aaty 80 mg/0.8 mL:</b> 1-Pen Kit CD/UC/HS Starter Kit	72606-0040-04 72606-0040-06
<b>Adalimumab-aaty 40 mg/0.4 mL:</b> 2-Syringe Kit 1-Pen Kit 2-Pen Kit	72606-0022-06 72606-0022-09 72606-0022-10
<b>Adalimumab-aaty 20 mg/0.2 mL:</b> Auto-Injector Kit Prefilled Syringe Kit Psoriasis/Uveitis Starter Kit Crohns/UC/HS Starter Kit	00597-0545-22 and 82009-0148-22 00597-0595-20 and 82009-0150-22 00597-0545-44 00597-0545-66
<b>Adalimumab-adbm 40 mg/0.4 mL:</b> Auto-Injector Kit Prefilled Syringe Kit Psoriasis/Uveitis Starter Kit Crohns/UC/HS Starter Kit	00597-0575-50 and 82009-0144-22 00597-0565-20 and 82009-0146-22 00597-0575-40 00597-0575-60

For a complete list of drugs and associated requirements, go to [2025 Drug Lists](#) for Medicare Members.

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.